Laughing Hyena
  • Home
  • Hyena Games
  • Esports
  • NFT Gaming
  • Crypto Trends
  • Game Reviews
  • Game Updates
  • GameFi Guides
  • Shop
Tag:

panel

SpaceX's Starship Lunar Lander Could Be ‘Years Late,’ NASA Safety Panel Warns
Product Reviews

SpaceX’s Starship Lunar Lander Could Be ‘Years Late,’ NASA Safety Panel Warns

by admin September 22, 2025


NASA aims to return astronauts to the Moon by mid-2027—a feat that would fulfill a decade of preparation. The agency may have to extend that timeline even further, however, as slow progress on SpaceX’s lunar lander threatens to delay the Artemis 3 mission.

During a public meeting on Friday, members of the Aerospace Safety Advisory Panel warned that the Human Landing System (HLS) version of Starship could be “years late,” SpaceNews reports. The panel reached that conclusion following a visit last month to SpaceX’s Starbase facility in Texas.

“The HLS schedule is significantly challenged and, in our estimation, could be years late for a 2027 Artemis 3 Moon landing,” said panelist Paul Hill, former director of Mission Operations at NASA.

Another Artemis delay—so what?

Putting American boots back on the Moon is a top priority for NASA. With a new space race underway, global powers including the U.S., China, and Russia are vying for a first-mover advantage.

Whoever reaches the lunar surface first will be able to set certain ground rules about who can do what and where. This would not only reinforce that country’s influence on the Moon and in space but also give it strategic leverage as military operations increasingly depend on space-based assets.

“This is a pivotal moment for our nation’s space program,” said Senate Commerce Committee Chairman Sen. Ted Cruz (R-Texas) during a hearing on legislative priorities for NASA earlier this month. He went on to emphasize that space has become a “strategic frontier with direct consequences for national security, economic growth, and technological leadership.”

How did we get here?

In 2021, NASA contracted Elon Musk’s SpaceX to build a version of Starship capable of landing astronauts on the Moon. At that time, the agency aimed to accomplish a landing by 2024, but that target date has been pushed back in recent years.

Development of Starship HLS has slowed significantly as SpaceX has struggled with repeated explosive failures this year. While Starship’s most recent test flight on August 26 was a success, unmet technical milestones have piled up.

One major issue is demonstrating the cryogenic propellant transfer needed to refuel Starship in low-Earth orbit before the rocket heads to the Moon, Hill said during the Friday meeting. Developmental delays for Starship 3—the first iteration capable of in-orbit fuel transfers—have slowed progress toward this goal.

Hill also pointed to potentially competing priorities for SpaceX between Starlink and Starship HLS, SpacePolicyOnline.com reports. Starship 3 will be integral in launching the third generation of Starlink satellites while simultaneously creating the on-orbit fuel depots and lunar lander for Artemis 3.

“The next six months of Starship launches will be telling about the likelihood of HLS flying crew in 2027 or by the end of the decade,” Hill said.

Despite these concerns, the panelists emphasized that SpaceX is still the only launch provider for the job. “There is no competitor, whether government or industry, that has this full combination of factors that yield this high a manufacturing and flight tempo, with their direct effects on reliability increases and cost reduction,” Hill said.

The downside to relying on SpaceX, however, is clear: Without a launch-ready Starship HLS by 2027, Artemis 3 won’t get off the ground on time.

Back in 2023, NASA selected Jeff Bezos’s Blue Origin to provide a second lunar lander, dubbed Blue Ghost, to be used during the Artemis 5 mission later this decade. The contract is worth $3.4 billion and includes a development team consisting of Lockheed Martin, Boeing, Draper, Astrobotic, and Honeybee Robotics.



Source link

September 22, 2025 0 comments
0 FacebookTwitterPinterestEmail
Crypto
Crypto Trends

Crypto Heavyweights Join CFTC’s Global Advisory Panel – Details

by admin September 21, 2025


Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

The US Commodity Futures Trading Commission (CFTC), announced new appointments to its Global Markets Advisory Committee and the Digital Asset Markets Subcommittee on September 19, 2025. The move brings fresh faces from both crypto and Wall Street firms into roles intended to advise the agency on digital asset issues.

New Leadership And Who They Are

Reports have disclosed that Scott Lucas, Managing Director and Head of Markets Digital Assets at J.P. Morgan, and Sandy Kaul, Executive Vice President at Franklin Templeton, will serve as co-chairs of the Digital Asset Markets Subcommittee.

In addition, the CFTC named several industry figures to the panel, including Katherine Minarik of Uniswap Labs, Avery Ching of Aptos Labs, James J. Hill from BNY Mellon, and Ben Sherwin of Chainlink Labs. The appointments were announced by Acting Chair Caroline D. Pham.

The list includes eight new members overall. Some come from traditional banks and asset managers. Others come from decentralized finance and infrastructure projects.

Congrats to @chainlinklabs General Counsel Ben Sherwin on his appointment to the @CFTC’s Digital Asset Markets Subcommittee of the Global Markets Advisory Committee! 🇺🇸 @chainlink https://t.co/aqcrasmOwb

— Caroline D. Pham (@CarolineDPham) September 19, 2025

Why This Matters Now

Based on reports, the appointments arrive as the CFTC pushes to play a larger role in how crypto markets operate in the US.

The agency has recently signaled that it will explore allowing spot crypto trading on registered futures exchanges — an initiative that could change which regulator oversees certain crypto products. That initiative was described in agency statements and industry coverage earlier this year.

Acting Chair Pham has also framed the advisory group as a bridge between market practice and rulemaking. She said the committee “provides invaluable expertise” that helps the agency weigh market structure and the regulatory treatment of digital assets.

As of today, the market cap of cryptocurrencies stood at $3.98 trillion. Chart: TradingView

Balance Of Interests In The Room

Bringing JPMorgan and Franklin Templeton together with Uniswap and Chainlink highlights a core tension. Market firms want clear rules that let them operate here.

Consumer groups and some regulators want stronger safeguards. Advisory committees do not make law; they advise. Still, their views can shape what rules are written next.

Some coverage also notes a practical reason for leaning on advisory bodies: the agency still has leadership gaps. Reports say several commissioner seats remain unfilled, which puts more weight on staff and outside advisers while those appointments are pending.

The appointments mark another step in a wider push to fold crypto more firmly into US markets. Whether that leads to faster approvals for new trading venues, or to stricter rules, will depend on how the committee’s recommendations are used by regulators.

Featured image from Jhvephotos | Dreamstime.com, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.





Source link

September 21, 2025 0 comments
0 FacebookTwitterPinterestEmail
CDC Panel Votes to Nix Current Covid Vaccine Recommendations
Gaming Gear

CDC Panel Votes to Nix Current Covid Vaccine Recommendations

by admin September 20, 2025


On Friday, the Advisory Committee on Immunization Practices (ACIP) voted to drop its recommendation that U.S. adults should generally receive the covid-19 vaccine, instead endorsing an individualized approach.

In a unanimous decision, the ACIP members agreed that adults 65 and older should decide on their own or with their doctor whether to get vaccinated for covid-19. The ACIP also recommended that people between the ages of 6 months and 64 years make an individual decision about covid-19 vaccination (yes, you read that correctly), while being informed that the benefits of vaccination are most apparent in those at higher risk of severe illness.

A screencap of ACIP blurbage articulating the new recommendations. © ACIP

The ACIP narrowly avoided recommending that Americans should require a prescription to get the covid-19 shot, however, though only barely.

A chaotic ACIP meeting

The votes capped off a chaotic and disorganized discussion held Friday over the safety and effectiveness of the covid-19 mRNA vaccines.

Retsef Levi, a longtime skeptic of the covid-19 vaccines and a professor of operations management at MIT Sloan School of Management, led the ACIP discussion, as well as the working group on covid-19 vaccines. Levi is one of several ACIP members handpicked by Health Secretary Robert Kennedy Jr. who has a long history of misrepresenting vaccine research.

CDC staff presented reams of evidence that covid-19 vaccines, even today, still reliably prevent serious outcomes like hospitalization and death, including in very young children. Many outside experts also testified in support of maintaining widespread access to these vaccines for every American who wants them. But ACIP members often questioned the findings or made their own poorly evidenced attempts to attack the safety of the vaccines.

At one point, for instance, ACIP members argued in support of a paper claiming to show extensive DNA contamination of the vaccines—a study that outside experts have criticized for glaring flaws and that is now being reviewed over potential concerns by its publisher. At another point, members argued that the covid-19 vaccines could possibly raise the risk of cancer, a claim widely refuted by most experts (mRNA vaccine technology is actively being studied as a way to prevent and treat certain cancers).

What this vote means for covid vaccine access

The language of the ACIP votes today was not disclosed until the very last minute, and it’s not entirely clear how they will impact vaccine access.

Late last month, the Food and Drug Administration limited its explicit approval of the updated covid-19 boosters to people over 65 or those with a higher risk of severe illness. The ACIP’s recommendation to move to an individualized approach, assuming it’s adopted by the CDC, may further delay or prevent people from obtaining a covid-19 booster if they so choose.

That said, several states like New York have already taken steps to ensure continued vaccine access and public coverage of the vaccine to all their residents. This week, the country’s largest health insurance association, America’s Health Insurance Plans, also announced that its members will rely on the previous ACIP recommendations to determine their coverage of the covid-19 vaccine for the time being. It additionally stated that patients covered by these plans would not experience cost-sharing through the end of 2026.

In a 6 to 6 vote, the ACIP declined to endorse a recommendation calling for people to require a prescription for the covid-19 vaccines—ACIP chairman Martin Kulldorff issued the tiebreaker, voting “no.”



Source link

September 20, 2025 0 comments
0 FacebookTwitterPinterestEmail
RFK Jr.’s Vaccine Panel Votes Down Its Own Proposal to Require Prescriptions for Covid-19 Shots
Product Reviews

RFK Jr.’s Vaccine Panel Votes Down Its Own Proposal to Require Prescriptions for Covid-19 Shots

by admin September 19, 2025


In another vote, advisers recommended adding language on the shot’s risks to the vaccine’s information sheet, which is already required by law.

The committee’s focus on Covid-19 vaccines reflects Kennedy’s long-held suspicion of them. Since taking office in February, Kennedy has canceled a half-billion dollars in mRNA vaccine research and separately ended a major contract with Moderna, one of the Covid vaccine manufactures, for work on a pandemic bird flu vaccine.

During Friday’s meeting, CDC scientists presented extensive data on the safety and efficacy of the Covid vaccines. They also explained in detail how the agency tracks Covid hospitalizations and said the agency has a “rigorous and standardized process” to determine whether hospitalizations are classified as being due to Covid-19.

During the discussion portion of the meeting, committee members made several unfounded claims. Robert Malone, a former mRNA researcher who has spread vaccine misinformation, questioned whether there is actually evidence of disease protection from the Covid shots. “Are there any well-defined, characterized correlates of protection for Covid, yes or no?” he demanded.

Cody Meissner, a pediatrician at Dartmouth College, responded that there is “a reasonable measurement of neutralizing or binding antibodies that correlate with protection against symptomatic infection in the first few months” after vaccination.

At one point, Hilary Blackburn, a pharmacist on the committee, questioned whether the Covid vaccine could be connected to her mother’s lung cancer diagnosis, which occurred two years after receiving a Covid vaccine. She said she is aware of four other individuals in her small hometown diagnosed with the same kind of cancer. “Is it related to the vaccine?” she asked.

In a tense exchange about potential birth defects associated with the Covid vaccines, some ACIP members pressed manufacturer Pfizer about eight birth defects that occurred in a group of pregnant women who received the company’s vaccine and two birth defects that occurred in an unvaccinated group. Alejandra Gurtman, who heads vaccine clinical research and development at Pfizer, replied that those rates are comparable to rates of congenital abnormalities seen in the general population.

Carol Hayes, a liaison with the American College of Nurse-Midwives who was present during the meeting, clarified that most birth defects arise during the first trimester of pregnancy, and in the cited study, mothers received the vaccine at 12 to 24 weeks of pregnancy.

At Friday’s meeting, the committee also reversed a decision it made just a day before. On Thursday, advisers voted to no longer recommend the combined measles, mumps, rubella, and varicella (MMRV) vaccine to children under age 4. Yet puzzlingly, it voted to maintain coverage of that vaccine through the federal Vaccines for Children program, which provides free vaccines to low-income children and those without insurance. On Friday, they voted that the program should not, in fact, cover it.

On Friday, advisers also voted 11 to one in favor of tabling a decision on whether to delay the birth dose of the hepatitis B vaccine until one month of age. The committee had discussed that vaccine extensively on Thursday, though it’s unclear why the committee was asked to look into the potential change at all, as the hepatitis B vaccine has been given to newborns in the US since 1991.

Infants get the vaccine before leaving the hospital because the virus can be passed from an infected mother to the baby during birth. Hepatitis B is a serious liver infection that can lead to cirrhosis and cancer. The vaccine is highly effective at preventing infection in newborns.

Chari Cohen, president of the Hepatitis B Foundation, tells WIRED there is no scientific rationale for delaying the hepatitis B vaccine until one month after birth and she worries about an increase in hepatitis B infections if the panel eventually recommends delaying the immunization.

“We will likely see more babies and young children who become infected,” Cohen says. “From a public health infrastructure perspective, we are concerned that this risk-based approach will miss preventing infection to babies born to infected moms.”

Up to 16 percent of HBV-positive pregnant women don’t get tested for hepatitis B, so screening doesn’t capture all infected mothers.

“We do not understand the motivation or rationale for this debate,” Cohen says.



Source link

September 19, 2025 0 comments
0 FacebookTwitterPinterestEmail
RFK Jr.’s Handpicked Vaccine Panel Nixes Measles-Chickenpox Combo for Kids Under 4
Product Reviews

RFK Jr.’s Handpicked Vaccine Panel Nixes Measles-Chickenpox Combo for Kids Under 4

by admin September 19, 2025


Robert F. Kennedy Jr.’s handpicked vaccine recommendation panel has just issued guidance that, if acted on, could overhaul when and how children receive vaccines designed to protect them from dangerous diseases like measles, rubella, and chickenpox.

The Advisory Committee on Immunization Practices (ACIP) met on Thursday. In an 8 to 3 vote, they recommended against the use of the combined measles, mumps, rubella, and varicella (chickenpox) vaccine in children under four. They are instead now recommending that children should only receive two separate vaccines covering these four diseases.

Kennedy’s new guard

The ACIP has traditionally been a panel of independent experts organized by the Centers for Disease Control and Prevention to help steer the country’s vaccine policy. Their recommendations, while non-binding, carry significant weight; many states mandate that children receive all the vaccines recommended by ACIP before entering public school, for instance. But under U.S. Health and Human Services Secretary Robert F. Kennedy, Jr., critics say that ACIP has become a platform for vaccine skepticism.

In early June, Kennedy unilaterally fired all 17 former members of ACIP and then, without any outside review, appointed eight new members, some of whom have previously misrepresented science on vaccine safety or who have financially benefited from attacking vaccines. Kennedy added five new members to the panel earlier this week, including some individuals who have questioned the safety and effectiveness of the covid-19 vaccines.

At the panel’s last meeting in June, in a majority vote, Kennedy’s new members recommended the removal of a mercury-based additive called thimerosal from the very few remaining vaccines that contain it. The recommendation was formally adopted by the government in July. Anti-vaccination proponents have long blamed thimerosal in vaccines for causing autism and other neurological conditions, even after it was phased out from all childhood shots two decades ago out of an abundance of caution. And dozens of studies have since failed to support any link between thimerosal (or, for that matter, any vaccine or specific ingredient) and autism.

Under Kennedy’s leadership, the CDC has been rocked by a series of high-profile departures. The Centers’ director Susan Monarez was reportedly fired for reportedly refusing to support Kennedy’s vaccine agenda—a decision that spurred the resignation of several other senior CDC staff and an unprecedented public display of support from remaining employees.

Monarez testified at a Senate hearing earlier this week, alleging that Kennedy had pressured her to rubber-stamp recommendations from ACIP. She also stated that Kennedy told her that the childhood vaccine schedule was going to change in September and that she needed to be “on board with it.”

What the latest vote means for these vaccines

In what was its second meeting since Kennedy dismissed the former members in June, the panel first debated the safety of the measles, mumps, rubella, and varicella (MMRV) vaccine.

The MMRV vaccine was approved in 2005 as a convenient alternative to children being given the MMR vaccine and a separate varicella vaccine, providing protection against all four diseases at once. Soon after its release to the public, however, evidence emerged that the first dose of the MMRV vaccine is associated with a slightly increased risk of febrile seizure (seizures caused by a fever) in children under the age of four as compared to the MMR plus varicella vaccine. Importantly, an additional risk of seizure wasn’t seen with the second dose of the MMRV vaccine given to older children.

The CDC was the first to discover and acknowledge this risk and has long recommended that, unless parents specifically request the MMRV vaccines, younger children should receive the MMR plus varicella vaccine as their first dose and the combined MMRV vaccine for the second dose. At Thursday’s ACIP meeting, CDC staff presented data showing that about 85% of parents choose the MMR and a separate varicella vaccine as recommended for the first dose. But since some families may prefer their children taking fewer vaccines overall, parents were advised they could opt for either vaccine strategy.

Febrile seizures are certainly scary for both the parent and for the child to experience. However, they’re generally short-lasting and aren’t often linked to longer-term health problems. In turn, the vast majority of these kinds of seizures aren’t tied to vaccination but to infections.

The long and short of it is that this change is wholly unnecessary, given that most parents take the CDC’s advice and don’t use the MMRV vaccine for the first dose. But the ACIP’s vote will effectively remove a family’s right to decide which shot their young children receive—an ironic fate given how anti-vaccination proponents often frame their decision to not vaccinate themselves or their children as an expression of freedom.

CDC staff noted that the ACIP’s recommendation could affect Medicaid coverage of these vaccines, as well as coverage offered through the Vaccines for Children (VFC) program, a federal program that provides vaccines to families unable to afford them. And it’s possible that some children who would have received the MMRV vaccine will end up not receiving the two separate vaccines for any number of reasons.

That said, the ACIP voted ‘No’ on whether the VFC should change its coverage in alignment with the new recommendation. This means that the program should stick to its existing coverage of the MMRV vaccine.

The ACIP also discussed whether it should continue to recommend universal hepatitis B vaccination starting at birth—a policy first endorsed by the group over 30 years ago. But due to a longer meeting than scheduled, the ACIP has delayed its vote on the matter until tomorrow. The ACIP is expected to weigh in on the covid-19 vaccines tomorrow as well.



Source link

September 19, 2025 0 comments
0 FacebookTwitterPinterestEmail
Vaccine Panel Stacked by RFK Jr. Recommends Delaying MMRV Immunization
Product Reviews

Vaccine Panel Stacked by RFK Jr. Recommends Delaying MMRV Immunization

by admin September 19, 2025


A federal vaccine advisory committee made up of members hand-picked by Health and Human Services secretary Robert F. Kennedy Jr. recommended in an 8-3 vote on Thursday that the combined measles, mumps, rubella, and varicella (MMRV) vaccine should not be given before age 4, citing long-known evidence that shows a slightly increased risk for febrile seizures in that age group.

Experts say that while frightening, febrile seizures—which are uncommon after vaccination—are usually short-lived and harmless, and removing the option for parents could cause a decline in immunization rates against measles, mumps, and rubella, some of the most dangerous childhood diseases.

Known as the Advisory Committee on Immunization Practices, or ACIP, the group provides recommendations to the US Centers for Disease Control and Prevention on vaccine usage. These recommendations are typically adopted by CDC and have an impact on state vaccine requirements for school, insurance coverage of vaccines, and pharmacy access—something at least one member of the panel seemed to be unaware of.

Thursday’s vote is part of a new shift in vaccine policy being spearheaded by Kennedy, a longtime anti-vaccine activist. In his short time as HHS secretary, Kennedy has implemented restrictions on who can receive Covid-19 vaccines and dismissed all 17 sitting members of ACIP, replacing them with 12 new members—some of whom were installed just this week. Several of the new advisers have a history of criticizing vaccines or denouncing public health measures taken during the Covid-19 pandemic. Kennedy said a “clean sweep” of ACIP was necessary to build back public confidence in vaccine science.

On Thursday, committee members were asked to evaluate whether to recommend against the combined MMRV vaccine before age 4, as well as whether to delay the first dose of the hepatitis B vaccine until the child is at least one month old.

Currently, parents have two options for vaccinating their children against measles, mumps, rubella, and varicella, also known as chickenpox. They can choose the combined shot, known as MMRV, or two separate shots—one for MMR and another for chickenpox. About 85 percent of children get separate shots.

In the US, the hepatitis B vaccine is given in the hospital shortly after birth, because the virus can be transmitted to children during delivery. A serious liver infection, hepatitis B can lead to cirrhosis and cancer. Each year in the US, an estimated 25,000 infants are born to women diagnosed with the hepatitis B virus. Without vaccination, up to 90 percent of them would develop chronic infections. The World Health Organization advises a universal birth dose of the hepatitis B vaccine.

The topics of discussion at Tuesday’s meeting were not based on new data or evidence, and in fact, two ACIP members, Joseph Hibbeln and Cody Meissner, as well as several representatives from professional medical organizations who were in attendance, questioned why these changes were up for consideration.

Robert Malone, one of the more controversial new ACIP members, offered an explanation: “It’s clear that a significant population of the United States has significant concerns about vaccine policy and about vaccine mandates.” Malone is a former mRNA researcher who rose to prominence during the Covid-19 pandemic by spreading falsehoods about the disease and the vaccines; he abstained from Thursday’s vote because he previously served as an expert witness in a lawsuit over the mumps vaccine.



Source link

September 19, 2025 0 comments
0 FacebookTwitterPinterestEmail
Nvidia’s app gets global DLSS override and more control panel features
Gaming Gear

Nvidia’s app gets global DLSS override and more control panel features

by admin August 19, 2025


The Nvidia app is getting improvements to DLSS override, more control panel features, and Project G-Assist changes this week. Nvidia has been gradually improving its new app over the past 18 months since its release, and it’s getting closer to fully migrating all the legacy control panel options.

This week’s Nvidia app update will include anisotropic filtering, anti-aliasing, and ambient occlusion options, meaning you won’t have to navigate to Nvidia’s older control panel app to improve classic games. The setup tool for Nvidia Surround will also be part of the Nvidia app now.

You also won’t have to configure DLSS override features on a per game basis anymore, as Nvidia is now adding a global option. You can set your DLSS preferences across all override supported games, and Nvidia’s overlay will also show which DLSS settings are active if you toggle this option on.

Nvidia is also bringing its new Smooth Motion feature, which was previously exclusive to RTX 50-series GPUs, to all RTX 40-series owners. It’s a driver-based AI model that enables smoother gameplay for games that don’t support DLSS Frame Generation. Smooth Motion can be applied to games running with DLSS Super Resolution, at native resolution, or even titles with other upscaling technologies. Nvidia says it will typically double “the perceived frame rate.”

If you’re a fan of Nvidia’s G-Assist AI assistant, Nvidia is changing the AI model behind the scenes so it will use 40 percent less memory. The smaller footprint won’t affect performance either, as it’s designed to respond even faster to queries.

These latest Nvidia app changes will arrive on August 19th for beta users at 9AM PT / 12PM ET, followed by a general release next week.



Source link

August 19, 2025 0 comments
0 FacebookTwitterPinterestEmail

Categories

  • Crypto Trends (1,098)
  • Esports (800)
  • Game Reviews (772)
  • Game Updates (906)
  • GameFi Guides (1,058)
  • Gaming Gear (960)
  • NFT Gaming (1,079)
  • Product Reviews (960)

Recent Posts

  • This 5-Star Dell Laptop Bundle (64GB RAM, 2TB SSD) Sees 72% Cut, From Above MacBook Pricing to Practically a Steal
  • Blue Protocol: Star Resonance is finally out in the west and off to a strong start on Steam, but was the MMORPG worth the wait?
  • How to Unblock OpenAI’s Sora 2 If You’re Outside the US and Canada
  • Final Fantasy 7 Remake and Rebirth finally available as physical double pack on PS5
  • The 10 Most Valuable Cards

Recent Posts

  • This 5-Star Dell Laptop Bundle (64GB RAM, 2TB SSD) Sees 72% Cut, From Above MacBook Pricing to Practically a Steal

    October 10, 2025
  • Blue Protocol: Star Resonance is finally out in the west and off to a strong start on Steam, but was the MMORPG worth the wait?

    October 10, 2025
  • How to Unblock OpenAI’s Sora 2 If You’re Outside the US and Canada

    October 10, 2025
  • Final Fantasy 7 Remake and Rebirth finally available as physical double pack on PS5

    October 10, 2025
  • The 10 Most Valuable Cards

    October 10, 2025

Newsletter

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

About me

Welcome to Laughinghyena.io, your ultimate destination for the latest in blockchain gaming and gaming products. We’re passionate about the future of gaming, where decentralized technology empowers players to own, trade, and thrive in virtual worlds.

Recent Posts

  • This 5-Star Dell Laptop Bundle (64GB RAM, 2TB SSD) Sees 72% Cut, From Above MacBook Pricing to Practically a Steal

    October 10, 2025
  • Blue Protocol: Star Resonance is finally out in the west and off to a strong start on Steam, but was the MMORPG worth the wait?

    October 10, 2025

Newsletter

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

@2025 laughinghyena- All Right Reserved. Designed and Developed by Pro


Back To Top
Laughing Hyena
  • Home
  • Hyena Games
  • Esports
  • NFT Gaming
  • Crypto Trends
  • Game Reviews
  • Game Updates
  • GameFi Guides
  • Shop

Shopping Cart

Close

No products in the cart.

Close